ArticleJournal of cancer research and clinical oncology2026
Clinicopathological features and prognostic analysis of 30 patients with laryngeal and hypopharyngeal adenoid cystic carcinoma: a single-center retrospective study.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo evaluate clinical characteristics, treatment outcomes, and prognostic factors in patients with laryngeal and hypopharyngeal adenoid cystic carcinoma (LHACC).
methodsThis retrospective, single-institution study (2013–2023) included patients with pathologically confirmed LHACC who underwent primary surgical treatment. Clinical and pathological variables were reviewed, and relevant gene alterations were extracted from cBioPortal. Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan–Meier curves and compared by the log-rank test.
resultsThirty patients were analyzed (median follow-up, 36 months; range, 4–130). The cohort comprised 10 men and 20 women (mean age 51 years). Hoarseness (36.7%) was the most frequent symptom and correlated with poorer OS (P = 0.033). Locoregional recurrence occurred in 5 patients (16.7%), and distant metastases in 15 (50%). OS rates at 3, 5, and 10 years were 95.5%, 76.4%, and 38.2%; DFS rates were 79.2%, 49.4%, and 10.3%. Survival rates were estimated using the Kaplan–Meier method, with 9 censored patients who had follow-up shorter than 3 or 5 years without tumor progression or death. Higher Ki-67 index (> 15%) predicted an unfavorable DFS (P = 0.041). Gene fusions (4 MYB–NFIB, 1 CTNNA3–NFIB) were detected in 50% of tested cases, highlighting molecular features of LHACC.
conclusionsHoarseness and Ki-67 may help identify high-risk LHACC patients. Surgical resection remains the cornerstone of therapy, but individualized management and long-term follow-up are essential. Frequent MYB–NFIB fusions underscore the molecular basis of LHACC and may inform future prognostic assessment and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.